REX LLY Growth & Income ETF
LLII
Chicago Board Options Exchange- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management - Income
- Address
- 1241 Post Road Fairfield WY United States of America 6824
- IPO Date
- Nov 4, 2025
- Website
- rexshares.com
- Similar Companies
- Business
- REX LLY Growth & Income ETF, LLC (LLII) operates as an actively managed exchange-traded fund that seeks to deliver weekly distributions while targeting 105% to 150% of the daily performance of Eli Lilly and Company (NYSE: LLY) through a synthetic covered call strategy and leveraged exposure. The fund aims to provide income generation via option writing on a portion of its equity exposure and, where available, may employ leveraged ETFs to achieve the desired notional exposure. LLII's structure combines direct equity ownership of LLY with derivative instruments and swaps to attempt to maintain 105%–150% notional exposure on a daily basis, balancing income with potential upside participation in the underlying stock. The fund is managed by an adviser responsible for determining appropriate leverage levels and rebalancing the portfolio to maintain the targeted exposure, and it seeks to optimize weekly distributions for investors. Founding year and headquarters: The fund family establishing LLII is headquartered in the United States; LLII began trading in November 2025. The issuer’s primary listing and operations are in the United States, with a focus on U.S. equity exposure through LLY and related derivatives, and a mandate to generate ongoing income for shareholders on a weekly cadence. Primary business activity and products: LLII provides a single-asset, covered-call driven equity strategy expressed through an ETF vehicle. Core product features include weekly income distributions; equity exposure to Eli Lilly and Company (LLY) via common stock ownership; a synthetic covered-call program using exchange-traded options and related derivatives; potential incorporation of leveraged exposure to the underlying when available; daily rebalancing to maintain the target 105%–150% notional exposure; and transparent disclosure of holdings, performance, and risk characteristics. The fund’s product set is centered on one underlying equity and a systematic income-focused derivatives program designed to deliver income while preserving growth potential relative to a traditional covered-call approach. LLII is designed for investors seeking income generation with a healthcare equity tilt and a governance framework typical of actively managed ETFs. Geographic and market scope: LLII markets to U.S.-based investors and operates within U.S. capital markets. Its underlying exposure is concentrated on a single U.S. healthcare stock, Eli Lilly and Company (LLY), reflecting a national investment focus with international visibility through LLY’s global operations. Industry and business segments: Financial instruments and exchange-traded products; equities with a healthcare/biopharmaceutical emphasis through LLY exposure; leveraged and synthetic exposure strategies via options and swap-like instruments; income-focused ETF sector with weekly distribution objective. Subsidiaries and parent relationships: LLII is issued by a sponsor and managed by a registered investment adviser within the REX framework. The trust structure and fund sponsor align with other REX Growth & Income ETFs, sharing a platform and governance practices designed for actively managed, income-oriented ETFs. REX Advisers, LLC serves as investment adviser responsible for strategy implementation, including leverage decisions and daily rebalancing. Recent major changes and developments: In the last 1–2 years, LLII has undergone launch and initial capitalization activities, including inception announcements, allocation to a covered-call and leveraged exposure model, and ongoing enhancements to its distribution policy. The fund has also announced and implemented a strategy to deliver weekly distributions through a synthetic covered-call framework while maintaining elevated but capped exposure to LLY, with ongoing disclosures of holdings, performance, and risk metrics. Notable operational changes include establishment of a formal distribution strategy, ongoing refinement of leverage targets, and systematization of daily rebalancing processes to sustain 105%–150% exposure. Target markets and customers: LLII targets investors seeking income generation with a healthcare equity tilt, including retail and institutional participants interested in weekly distributions and an actively managed covered-call strategy. The product is positioned for investors seeking predictable income streams, potential upside participation, and exposure to a top-tier pharmaceutical company. Key performance and risk considerations: LLII operates with a notional exposure model designed to deliver weekly income while attempting to match 105%–150% of LLY’s daily performance. The use of options and leverage introduces complexities including accelerated risk and reward profiles relative to direct LLY ownership. Investors should consider equity and options risk, leverage-related volatility, and concentration risk due to single-stock exposure. The fund provides performance disclosures and risks as part of its regular investor communications and regulatory filings.